Effect of garlic powder in treatment of non alcoholic fatty liver

The effect of garlic powder supplementation on body composition, liver echogenicity, insulin resistance, liver enzymes, lipid profile and oxidative stress in patients with non alcoholic fatty liver disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170206032417N4

Enrollment

Registered

2019-04-28

Start date

2018-10-23

Completion date

Unknown

Last updated

2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: The intervention group will be consume 4 tablets of 400 miligrams per day garlic in addition to usual treatment for three months. Intervention 2: Control group: The

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: patients with non alcoholic fatty liver disease age of between 18 and 75

Exclusion criteria

Exclusion criteria: alcohol use viral hepatitis hepatocellular carcinoma other causes of chronic liver disease diabetes mellitus untreated hypothyroidism psychiatric disorder kidney disease pregnancy lactation allergy to garlic patients with low blood pressure

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: At weeks 0, 6, 12. Method of measurement: scale. kg.;Body mass index. Timepoint: At weeks 0, 6, 12. Method of measurement: Weight(kg)\[height(m)]2 , kg\m2.;Gamma Glutamyl transferase. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method , IU\ Lit.;ALP. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method , IU\ Lit.;Aspartat transaminase. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, IU\ Lit.;Alanine Aminotransferase. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, IU\ Lit.;Fasting blood sugar. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, IU\ Lit.;Serum insulin. Timepoint: At weeks 0, 12. Method of measurement: Radioimmunoassay.;Body fat mass. Timepoint: At weeks 0, 6, 12. Method of measurement: BIA, kg.;Skeletal muscle mass. Timepoint: At weeks 0, 6, 12. Method of measurement: BIA, kg.;Waist circumference. Timepoint: At weeks 0, 6, 12. Method of measurement: BIA, cm.;Hepatic steatosis. Timepoint: Before intervention and three month after intervention. Method of measurement: Ultrasonography.;HDL cholesterol. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;Total antioxidant capacity. Timepoint: At weeks 0, 12. Method of measurement: spectrophotometry, Nmol/l.;SOD. Timepoint: At weeks 0, 12. Method of measurement: spectrophotometry, Nmol/l.;MDA. Timepoint: At weeks 0, 12. Method of measurement: spectrophotometry, Nmol/l.;Systolic blood pressure. Timepoint: At weeks 0, 6, 12. Method of measurement: Mercury sphygmomanometer, mmHg.;Diastolic blood pressure. Timepoint: At weeks 0, 6, 12. Method of measurement: Mercury sphygmomanometer, mmHg	—

Measure

Time frame

Weight. Timepoint: At weeks 0, 6, 12. Method of measurement: scale. kg.;Body mass index. Timepoint: At weeks 0, 6, 12. Method of measurement: Weight(kg)\[height(m)]2 , kg\m2.;Gamma Glutamyl transferase. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method , IU\ Lit.;ALP. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method , IU\ Lit.;Aspartat transaminase. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, IU\ Lit.;Alanine Aminotransferase. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, IU\ Lit.;Fasting blood sugar. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, IU\ Lit.;Serum insulin. Timepoint: At weeks 0, 12. Method of measurement: Radioimmunoassay.;Body fat mass. Timepoint: At weeks 0, 6, 12. Method of measurement: BIA, kg.;Skeletal muscle mass. Timepoint: At weeks 0, 6, 12. Method of measurement: BIA, kg.;Waist circumference. Timepoint: At weeks 0, 6, 12. Method of measurement: BIA, cm.;Hepatic steatosis. Timepoint: Before intervention and three month after intervention. Method of measurement: Ultrasonography.;HDL cholesterol. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;Total antioxidant capacity. Timepoint: At weeks 0, 12. Method of measurement: spectrophotometry, Nmol/l.;SOD. Timepoint: At weeks 0, 12. Method of measurement: spectrophotometry, Nmol/l.;MDA. Timepoint: At weeks 0, 12. Method of measurement: spectrophotometry, Nmol/l.;Systolic blood pressure. Timepoint: At weeks 0, 6, 12. Method of measurement: Mercury sphygmomanometer, mmHg.;Diastolic blood pressure. Timepoint: At weeks 0, 6, 12. Method of measurement: Mercury sphygmomanometer, mmHg

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Alizadeh

Oroumia University of Medical Sciences

alizadeh.m@umsu.ac.ir+98 44 3275 2375

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 27, 2026